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Abstract: Preventing the spread of multidrug-resistant Gram-negative bacteria (MDRGNB) is
a public health priority. However, the definition of MDRGNB applied for planning infection
prevention measures such as barrier precautions differs depending on national guidelines. This is
particularly relevant in the Dutch–German border region, where patients are transferred between
healthcare facilities located in the two different countries, because clinicians and infection control
personnel must understand antibiograms indicating MDRGNB from both sides of the border
and using both national guidelines. This retrospective study aimed to compare antibiograms of
Gram-negative bacteria and classify them using the Dutch and German national standards for
MDRGNB definition. A total of 31,787 antibiograms from six Dutch and four German hospitals were
classified. Overall, 73.7% were no MDRGNB according to both guidelines. According to the Dutch
and German guideline, 7772/31,787 (24.5%) and 4586/31,787 (12.9%) were MDRGNB, respectively
(p < 0.0001). Major divergent classifications were observed for extended-spectrum β-lactamase (ESBL)
-producing Enterobacteriaceae, non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae,
Pseudomonas aeruginosa and Stenotrophomonas maltophilia. The observed differences show that medical
staff must carefully check previous diagnostic findings when patients are transferred across the
Dutch–German border, as it cannot be assumed that MDRGNB requiring special hygiene precautions
are marked in the transferred antibiograms in accordance with both national guidelines.
Keywords: ESBL; carbapenemase; Euregio; multidrug resistance; Klebsiella; Escherichia coli;
Acinetobacter baumannii; Stenotrophomonas maltophilia; Enterobacteriaceae
1. Introduction
Antimicrobial multidrug-resistant Gram-negative bacteria (MDRGNB) globally challenge
clinicians and infection control personnel due to limited treatment options and the need to implement
barrier precautions for preventing MDRGNB transmission [1]. Comparing this challenge is particularly
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interesting in neighboring regions characterized by highly developed but structurally different
healthcare systems. An example for such a region is the Dutch–German border area, which is inhabited
by 12 million people and comprises >100 hospitals.
In The Netherlands and Germany, surveillance systems currently indicate that 7.0% and 11.8%
of all Escherichia coli and 10.8% and 14.3% of all Klebsiella pneumoniae isolated from blood cultures are
non-susceptible to third-generation-cephalosporins indicative for production of extended-spectrum
β-lactamases (ESBL) [2]. Moreover, carbapenemase-producing Enterobacteriaceae (CPE) occur in
both countries, although the overall meropenem or imipenem resistance rates of Enterobacteriaceae
(e.g., Klebsiella spp.) are still <1% [2]. Thirdly, carbapenem resistance in Acinetobacter baumannii, which
is often due to carbapenem-hydrolysing oxacillinase (OXA) production, affects 1.9% and 5.4% of all
invasive isolates in The Netherlands and Germany respectively [2]. A fourth clinically relevant species
is Pseudomonas aeruginosa. For this bacterium, 11% and 18% of all isolates from bloodstream infections
were non-susceptible to ceftazidime and meropenem in Germany, respectively. In contrast, resistance
rates were 3.5% and 6.1% in The Netherlands [2].
Nosocomial transmission is a major reason why the incidence of MDRGNB increases. Hence,
infection control guidelines describing measures to prevent MDRGNB dissemination are implemented
in many countries including The Netherlands and Germany. However, it should be noted that,
according to data from the European Centre for Disease Prevention and Control (ECDC), Germany
is currently considered as a country, where CPE are regionally endemic indicating inter-institutional
spread, while their occurrence is more limited in The Netherlands. The same is observed for
carbapenem-resistant A. baumannii [3]. This highlights the need to critically evaluate and compare
infection control guidelines, as well as different risks for MDRGNB spread in these two countries.
In this context, one aspect is the definition of MDRGNB. Although definitions for multidrug
resistance in epidemiological studies are available [4], and although theoretically CPE or
ESBL-producing Enterobacteriaceae are clearly defined by harboring respective resistance encoding
genes, the questions concerning what MDRGNB are in clinical routine and for which MDRGNB
special barrier precautions should be implemented, are not universally defined. Moreover, it is
important to differentiate between MDRGNB definitions established for therapeutic decisions and
those created for epidemiological purposes and infection prevention [4]. Recently, Mueller et al. have
pointed out differences between the Dutch and German guidelines regarding the advice they give to
laboratories and infection control personnel, which Gram-negative bacteria and antimicrobial resistance
patterns should be considered as MDRGNB [5]. As patient movement across the Dutch–German
border is not infrequent, such divergent definitions could result in reduced patient safety, because
isolates requiring isolation in the hospital abroad are not flagged as being multidrug-resistant on the
microbiological reports.
Hence, in this article, we collected antibiograms of Gram-negative bacteria from Dutch and
German hospitals located in the border region and applied both national MDRGNB definitions
for infection prevention measures on this dataset. The results of this comparison shall clarify the
differences between the two countries and estimate the impact of these differences for daily infection
control practice.
2. Materials and Methods
We retrospectively extracted antibiograms of Gram-negative bacteria from laboratory information
systems. Data about phenotypic and genotypic ESBL and carbapenemase tests performed for the
respective bacterial isolates were also extracted, if available. All isolates included originate from
patients treated in six Dutch and four German hospitals. All hospitals are located in the Dutch–German
border region including the Northern part (Ems Dollart region) and the central part (EUREGIO).
Five of six Dutch hospitals provided datasets from 1 January 2015 to 31 December 2016, because only
a small number of samples was tested in these facilities; the sixth Dutch hospital and the German
hospitals provided data for 2016 only. Antimicrobial susceptibility testing was done using guidelines
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of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines and clinical
breakpoints in all laboratories.
Anonymization of patient-related and hospital-related data was done before analysis. We initially
included all Gram-negative bacterial species and then restricted the dataset to Enterobacteriaceae,
P. aeruginosa, A. baumannii complex, and Stenotrophomonas maltophilia, as these are the species
for which recommendations regarding MDRGNB definitions and special hygiene precautions are
included in Dutch and German infection control guidelines [6,7]. We included all isolates; duplicate
isolates from the same patient were not removed. Classification of MDRGNB was done according
the German national guideline (MDRGNB classified according to this guideline are henceforth
designated “Multiresistente Gramnegative Stäbchen”, MRGN, with the subtypes 3MRGN and 4MRGN)
summarized in Table 1 [6] and according to the Dutch national guideline (MDRGNB according to
this guideline are henceforth designated “Bijzonder Resistente Micro-Organismen”, BRMO) shown in
Table 2 [7], for all isolates including complete phenotypic susceptibility test data for the antibiotics
mentioned. Incomplete antibiograms were deleted from the dataset.
Table 1. Classification according to German guideline into 3MRGN and 4MRGN.
Bacteria Categories 1 Classification
I II III IV 3MRGN 5 4MRGN 5





Resistance to four of
four categories or to
category IV alone
P. aeruginosa PIP TAZ and FEM CIP IMI and MER Resistance to threeof four categories
Resistance to four of
four categories
A. baumannii PIP 4 TAZ 4 CIP




Resistance to four of
four categories or to
category IV alone
1 PIP = piperacillin, TAX = cefotaxime, TAZ = ceftazidime, FEM = cefepime, CIP = ciprofloxacin, IMI = imipenem,
MER = meropenem, CARB = carbapenemase detected in the isolate irrespectively of the resistance phenotype,
intermediate test results are considered as resistant for the classification. 2 Enterobacteriaceae includes a classification
for the following species: E. coli, Klebsiella spp., Proteus spp., Citrobacter spp., Enterobacter spp. and E. cloacae,
S. marcescens, Morganella spp., Providencia spp. 3 Imipenem is not considered for Proteus spp., Morganella spp.,
S. marcescens, Providencia spp. 4 PIP and TAZ are always considered as resistant due to missing clinical breakpoints
for A. baumannii. 5 Special hygiene precautions are required for patients with 4MRGN in all parts of the hospital and
for patients with 3MRGN only on intensive care units or other units with immunocompromised patients according
to local risk assessments.
Table 2. Classification according to Dutch guideline into BRMO.
Bacteria Categories 1
ESBL CARB 1 FQ AM PIP TAZ SXT
Enterobacteriaceae 2 BRMO 3 BRMO BRMO: Resistance to FQ and AM 2 - -
P. aeruginosa - BRMO: Resistance to ≥3 categories: CARB 1, FQ; AM; PIP; TAZ -
A. baumannii - BRMO BRMO: Resistance to FQ and AM 2 - -
S. maltophilia - - - BRMO
1 CARB = carbapenemase, for Enterobacteriaceae at least OXA-48, Verona integron-encoded
metallo-β-lactamase (VIM), New Delhi metallo-β-lactamase (NDM), Klebsiella pneumoniae carbapenemase
(KPC), imipenem-carbapenemase (IMP) are tested; for P. aeruginosa at least VIM is tested, FQ = fluoroquinolones,
AM = aminoglycosides, PIP = piperacillin, TAZ = ceftazidime. 2 FQ includes ciprofloxacin (and levofloxacin for
A. baumannii); AM includes gentamicin and tobramycin (if tested both, resistance was assumed, if both were
resistant. If only one of these agents was tested, this result was used for classification). 3 Classification as BRMO
is followed by isolation in single-rooms (with anteroom) and barrier precautions for all A. baumannii and all
Enterobacteriaceae characterized by CARB. For all other BRMO, contact isolation is recommended and can be done in
single rooms or other rooms.
Statistical analysis was done by EpiInfo (version. 7.0, CDC Atlanta, Atlanta, GA, USA) using
Chi-Square or (where appropriate) Fisher’s exact test; p < 0.05 was considered significant. The final
dataset does not allow for conclusions about the epidemiology or the prevalence of MDRGNB,
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as it contains both isolates obtained from screening asymptomatic patients and clinical specimens.
Moreover, the diagnostic procedures and indications for screening and clinical diagnostics were not
harmonized in the participating laboratories and hospitals.
3. Results
3.1. Number of Antibiograms and Patients
Initially, 35,619 antibiograms were included of which 12,616 were from Dutch and 23,003 from
German hospitals. The 12,616 isolates were from five Dutch secondary-care hospitals (n = 4377;
from 2015 to 2016) and one Dutch university-hospital (n = 8239, 2016), and the 23,003 isolates were
from three German secondary-care hospitals (n = 6914, 2016) and one German university-hospital
(n = 16,089, 2016). Overall, 80.9% of all isolates were Enterobacteriaceae and 19.1% non-fermenting
Gram-negative bacteria.
When analyzing the data, two major limitations occurred: (i) For Enterobacteriaceae, the Dutch
classification system could not be applied for 3832 isolates, because they were not tested for the
presence of ESBLs or test results were unclear (n = 3720 isolates from the German hospitals and
n = 112 from Dutch hospitals). This is because testing for the presence of ESBL is not required by the
German MRGN classification system (and is often not performed in German laboratories except for
E. coli and Klebsiella spp., where this test is routinely implemented in automated systems used for
antimicrobial susceptibility testing). These isolates were therefore excluded from further analysis,
which reduced the total number of isolates analyzed to 31,787. (ii) Overall, we lacked data for the
results of carbapenemase PCRs for non-fermenting bacteria. As carbapenemase PCRs are not required
for classification in the German system, these results were not available for 4651 P. aeruginosa isolates
from German hospitals. Since no VIM-carbapenemase was reported for the 1205 P. aeruginosa isolates
from Dutch hospitals, we coped with this problem by assuming that the German P. aeruginosa isolates
were also VIM-negative and classified these isolates accordingly when applying the Dutch guideline.
In contrast, for A. baumannii, we considered all carbapenem-resistant isolates as carbapenemase
producers when applying the Dutch guidelines. For Enterobacteriaceae, test results were available,
because German laboratories test the isolates in line with quality management measures.
3.2. Results of MRGN and BRMO Classification
According to the Dutch classification system, 7,772/31,787 (24.5%) isolates were BRMO. Applying
the German classification system on the same antibiograms resulted in the identification of 4586/31l,787
(12.9%) MRGN (p < 0.0001). Table 3 shows where the two classification systems had the most divergent
results on genus or species level.
The distribution of 3MRGN and 4MRGN among the 4,586 MRGN isolates is shown in
Figure 1. Among all 152 carbapenem-resistant Enterobacteriaceae isolates, carbapenemases were
detected in 42 isolates (27.6%) with OXA-48-like genes being predominant. The remaining
110 isolates, were negative for carbapenemases (n = 87, 79.1%) or not tested (n = 23, 20.9%) and
were meropenem-non-susceptible Morganella, Proteus, Providencia, and Serratia (n = 45), as well as
Klebsiella spp. (n = 31), Enterobacter (n = 24), E. coli (n = 7), and Citrobacter (n = 3).
Of all 6882 isolates classified as BRMO-Enterobacteriaceae, 34 harbored carbapenemase-encoding
genes (0.5%), 4953 were ESBL-producers (80.0%), and 3037 (44.1%) isolates were simultaneously
resistant to fluoroquinolones and aminoglycosides. A total 788 P. aeruginosa isolates were classified
as BRMO, because they had a resistance pattern in accordance with Table 2. Among the remaining
5058 P. aeruginosa isolates (3961 from German and 1107 from Dutch laboratories) not classified as
BRMO, 1107 (21.9%) were carbapenem-resistant (981 and 126 from German and Dutch laboratories,
respectively). A total 72 BRMO-A. baumannii isolates were classified as such, because they were
carbapenem-resistant (n = 70), quinolone/aminoglycoside-resistant (n = 2) or both (n = 59).
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Table 3. Differences in using Dutch and German multidrug resistance classification systems.
Dutch Classification German Classification
BRMO 1 no BRMO 1 MRGN 1 no MRGN 1 p
A. baumannii 72 370 87 355 0.2202
Citrobacter spp. 79 626 71 634 0.5454
E. cloacae 146 972 154 964 0.6641
E. coli 5270 9606 2445 12,431 <0.0001
Enterobacter spp. 8 280 8 280 1
Hafnia spp. 1 44 0 45 1
K. oxytoca 75 1885 26 1934 0.0001
K. pneumoniae 877 2578 556 2899 <0.0001
Klebsiella spp. 0 17 0 17 1
Morganella spp. 45 226 20 251 0.0015
P. aeruginosa 788 5068 1108 4748 <0.0001
Proteus spp. 257 1009 81 1185 <0.0001
Providencia spp. 16 33 10 39 0.2526
S. maltophilia 30 471 0 501 <0.0001
Salmonella 95 17 11 101 <0.0001
S. marcescens 11 770 9 772 0.8219
Serratia spp. 2 43 0 45 0.4944
Total 7772 24,015 4586 27,201 <0.0001
1 BRMO = “Bijzonder Resistente Micro-Organismen”, according to Dutch classification system; MRGN =
“Multiresistente gramnegative Stäbchen”, according to German classification system. p < 0.05 in bold.
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Figure 1. S ecies istrib tio a o g isolates classifie as 3 a 4 accor i g to the
er an guideline.
However, of all isolates 23,433 (73.7%) were neither classified as MRGN, nor as BRMO. Among
3780 and 806 isolates classified as 3MRGN and 4MRGN according to the German guideline,
3271 (86.5%) and 733 (90.9%) were also classified as BRMO. In contrast, of the 7772 isolates classified as
BRMO, 3768 were not classified MRGN (48.5%). An agreement matrix between the Dutch and German
guidelines for MDRGNB classification is shown in Table 4.
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Table 4. Correlation matrix between the Dutch BRMO-classification and the German
MRGN-classification system to define multidrug-resistant Gram-negative bacteria (MDRGNB) for















Acinetobacter baumannii 98.6 100.0 5.9 100.0 81.6 80.1 442
Citrobacter spp. 54.4 100.0 58.8 100.0 60.6 84.8 705
Enterobacter cloacae 58.2 100.0 57.3 43.5 55.2 80.8 1118
Enterobacter spp. 12.5 100.0 16.7 0.0 12.5 94.8 288
Escherichia coli 45.5 100.0 98.3 37.5 98.1 63.3 14,876
Hafnia spp. 0.0 100.0 100.0 100.0 100.0 97.8 45
Klebsiella oxytoca 21.3 100.0 60.9 66.7 61.5 95.7 1960
Klebsiella pneumoniae 61.7 100.0 99.0 85.3 97.3 74.2 3455
Klebsiella spp. 100.0 100.0 100.0 100.0 100.0 100.0 17
Morganella spp. 33.3 100.0 67.0 100.0 75.0 81.5 271
Proteus spp. 30.0 100.0 96.6 91.3 95.1 79.4 1266
Providencia spp. 62.5 100.0 100.0 100.0 100.0 67.3 49
Pseudomonas aeruginosa 92.8 100.0 34.7 94.0 66.0 80.1 5856
Salmonella spp. 11.6 100.0 100.0 100.0 100.0 15.2 112
Serratia marcescens 36.4 100.0 100.0 28.6 44.4 98.0 781
Serratia spp. 0.0 100.0 100.0 100.0 100.0 95.6 45
Stenotrophomonas maltophilia 0.0 100.0 100.0 100.0 100.0 94.0 501
Legend ≥75.0% 25.0–74.9% <25.0%
1 Percentage of BRMO also classified as MRGN (including 3MRGN and 4MRGN). 2 Percentage of
carbapenemase-producing BRMO also classified as 4MRGN. 3 Percentage of 3MRGN, 4MRGN, and all MRGN also
classified as BRMO. 4 Percentage of isolates not classified as MDRGNB by both the Dutch and German definitions.
5 Number of isolates included for the respective species.
4. Discussion
When patients are transferred between hospitals, information regarding MDRGNB colonization or
infection must also be transferred to ensure continuous implementation of infection control measures.
This is usually supported by indicating on antibiograms, which are included in the records of a
transferred patient, whether the respective bacteria are multidrug-resistant according to the national
guideline. For cross-border healthcare, this implies that clinicians or infection control staff can interpret
antibiograms according to guidelines from both countries or understand foreign ‘MDRGNB languages’.
The aim of this study was to describe different classifications used in The Netherlands and Germany in
order to estimate the risk, which might be caused when patients infected or colonized with MDRGNB
are transferred across the border without recognizing the respective bacteria as multidrug-resistant.
When planning the data analysis, a first hurdle occurred when the authors tried to actually
understand the respective classification guidelines in detail. We learned that parts of the practical
applicability of the guidelines (from both sides of the border) are rather locally defined. For example,
in the Dutch guideline, it is not explicitly mentioned for Enterobacteriaceae, which fluoroquinolones
(e.g., ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin) and aminoglycosides (e.g., gentamicin,
tobramycin, amikacin) should be considered for the classification of which bacterial species and
how to categorize, if one quinolone is resistant and the other susceptible. In the German guideline,
some exceptional rules, such as ignoring imipenem non-susceptibility in Serratia or Proteus for the
classification (due to unreliable test results) are not mentioned, and can only be concluded from
other guidance papers or publications of German reference laboratories. This might cause problems
if microbiological laboratories are working across the border and might be perceived as a lack of
transparency. This issue could be improved when national policy makers published more detailed
standard operating procedures for laboratories where the problems occurring in daily routine are more
accurately described.
Overall, the Dutch guideline makes it more laborious for a microbiological laboratory to actually
classify an isolate as MDRGNB (tests for phenotypic ESBL-production and VIM-carbapenemase
encoding genes). This might reflect structural differences in the organization of microbiological
diagnostics between the two countries, as more laborious confirmation testing requires using more
financial resources.
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When comparing the Dutch and the German classification systems for MDRGNB (Table 4),
we found very divergent results.
The bulk of isolates, which were classified differently, were E. coli and Klebsiella isolates
characterized by ESBL-production, but being susceptible to fluoroquinolones. In German hospitals,
no other than basic hygiene measures are taken for patients colonized or infected with these strains.
This can be criticized, because spread of ESBL-producers might increase carbapenem use. Moreover,
ESBLs are usually encoded on plasmids, which can be transferred independently from the bacterial
clone even to other bacterial species. However, recent investigations have shown, that clonal spread of
ESBL-E. coli in healthcare settings is rarely observed [8,9]. A second reason for divergent classifications
was that the Dutch guideline uses combined fluoroquinolone and aminoglycoside resistance as a
criterion for multidrug resistance. Aminoglycosides are not considered in the German guideline,
maybe due to their limited and decreasing use in German hospitals compared with The Netherlands
(<0.5 vs. 3.7 daily defined doses (DDD)/100 patient-days) [10,11]. Thirdly, major differences were also
found for P. aeruginosa. Many of the very broadly resistant P. aeruginosa isolates, for which colistin,
tobramycin, or new β-lactams (such as ceftolozane/tazobactam) were the only remaining treatment
options, were not classified as MDRGNB by the Dutch guideline, because VIM-carbapenemases
were not detected. In this context, we clearly overestimated the disagreement between the Dutch
and German guideline (Table 4), because we considered all 1,107 carbapenem-resistant P. aeruginosa
isolates (of 5058 not classified as BRMO) as VIM-negative. This is not probable as it is well known
that in Germany up to 24% of carbapenem-resistant P. aeruginosa isolates harbor carbapenemases
among which VIM is predominant [12]. This points towards a major limitation of this study. Since
the analysis was not prospectively planned, we had to cope with missing data. Of course, excluding
3832 antibiograms (which is >10% of the antibiograms collected in the participating hospitals) due to a
lack of information about phenotypic ESBL-test results for non-E. coli/non-Klebsiella isolates might
have caused significant impact on the results. However, the total numbers Enterobacter, Citrobacter,
or Hafnia isolates included from both sides of the border was comparable. Overall, the results of this
study demonstrate that in contrast to other multidrug-resistant bacteria such as methicillin-resistant
Staphylococcus aureus or vancomycin-resistant enterococci, those resistance pheno- or genotypes that
define Gram-negative bacteria as MDRGNB markedly differ between The Netherlands and Germany.
For cross-border care, the easiest solution would be to harmonize the classification rules of both
countries. As long as this is not done, the full antibiogram data of Gram-negative bacteria should be
transferred together with the patient in order to enable classification by local infection control staff.
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